ACTIVE

Purna Pharmaceuticals

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result2,8 M €+4,2 %over 1 year

Revenue43,2 M €-5,9 %over 1 year

Equity19,4 M €+16,1 %over 1 year

Workforce182,6 ETP+0,8 %over 1 year

Identity

Source · BCE/KBO

Purna Pharmaceuticals is a Public limited company incorporated in 1986. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Puurs-Sint-Amands. It employs on average 182,6 ETP workers (FTE).

Legal situation: Normal situation
BCE/KBO no. / VAT: BE 0428.742.176
Incorporation: 04/04/1986
Legal form: Public limited company
Registered office: Rijksweg 17
2870 Puurs-Sint-Amands · FlandreSee on map
Contributed capital: 2 940 212,91 €
Latest accounts: 31/12/2025
Average workforce: 182,6 ETP

Activities (NACE)

21201Manufacture of pharmaceutical preparations· main 21201Manufacture of pharmaceutical preparations 21209Manufacture of pharmaceutical preparations 21209Manufacture of pharmaceutical preparations 24421Aluminium production 24422Aluminium production+3

Joint committees (2)

Signals

ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debtsHigh revenue

Financials

Source · NBB, 21 filings

Trend over 18 financial years

	2025		2024		2023		2022		2021
Income statement
Revenue	43,2 M €	-5.9%	45,9 M €	+21.7%	37,7 M €	+0.9%	37,4 M €	+10.7%	33,8 M €
EBITDA	6,5 M €	-5.3%	6,9 M €	+1506%	429 k €	-83.8%	2,6 M €	+14.2%	2,3 M €
Operating result	3,2 M €	-8.4%	3,5 M €	+226%	-2,8 M €	-652%	-370,5 k €	-86.1%	-199,2 k €
Net result	2,8 M €	+4.2%	2,7 M €	+180%	-3,4 M €	-353%	-745 k €	-29.4%	-575,6 k €
Balance sheet
Equity	19,4 M €	+16.1%	16,7 M €	+49.8%	11,1 M €	+36.3%	8,2 M €	-9.4%	9 M €
Total assets	34,3 M €	-5.1%	36,1 M €	+16.8%	31 M €	+15.4%	26,8 M €	+4.1%	25,8 M €
Cash	173,3 k €	+250%	49,5 k €	-22.2%	63,6 k €	+2.6%	62 k €	-77.5%	275,7 k €
Debts	13,1 M €	-26.4%	17,8 M €	-1.5%	18,1 M €	+3.7%	17,5 M €	+11.0%	15,7 M €
Other
Workforce	182,6 ETP	+0.8%	181,2 ETP	-4.0%	188,7 ETP	-1.0%	190,7 ETP	+2.5%	186,0 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 50 M€ and 100 M€

See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

6 active · 4 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
David J. Parker	Director20/02/2026 → 19/02/2032
Hidde Van Kerckhoven	Director20/01/2026 → 19/01/2032
Bart M.J. Peeters0871.617.848Represented by BART PEETERS	Managing director06/05/2021 → 06/05/2027Director04/01/2005 → 2017 accountsended
CREAFUND ASSET MANAGEMENT0679.859.835Represented by RUTH DE WULF	Director20/09/2018 → 06/05/2027
LEA SMETS	Director30/12/2003 → 06/05/2027
RAYMOND VAN GUCHT	Chairman of the board of directors06/05/2021 → 06/05/2027Managing director30/12/2003 → 2020 accountsended

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
CREALOAN0470.551.057Represented by HERMAN WIELFAERT	Director20/09/2018 → 2018 accounts
True North Asset Management0457.827.330Represented by Bernard Hendrickx	Director25/06/2018 → 20/09/2018
IFC Services0843.336.905Represented by Johan Heirbrandt	Director06/05/2015 → 2015 accounts

Other companies at this address

Rijksweg 17 2870 Puurs-Sint-Amands

Company	CBE no.
Inno Pharma● Active	0762.694.073
Montana BidCo● Active	1031.182.056

Full financial information

Source · NBB

	2025	2024	2023	2022	2021	2020
Type of account	Full model	Full model	Full model	Full model	Full model	Full model
Start of the financial year	01/01/2025	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020
Closing of the financial year	31/12/2025	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	05/06/2026	22/05/2025	07/06/2024	19/05/2023	13/06/2022	28/06/2021
General meeting	06/05/2026	06/05/2025	06/05/2024	10/05/2023	04/05/2022	05/05/2021
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 21 filings

Model	Closing	General meeting	Filed	Language	Document
Full model	31/12/2025	06/05/2026	05/06/2026	Dutch	PDF
Full model	31/12/2024	06/05/2025	22/05/2025	Dutch	PDF
Full model	31/12/2023	06/05/2024	07/06/2024	Dutch	PDF
Full model	31/12/2022	10/05/2023	19/05/2023	Dutch	PDF
Full model	31/12/2021	04/05/2022	13/06/2022	Dutch	PDF
Full model	31/12/2020	05/05/2021	28/06/2021	Dutch	PDF
Full model	31/12/2019	06/05/2020	06/07/2020	Dutch	PDF
Full model	31/12/2018	08/05/2019	12/06/2019	Dutch	PDF
Full model	31/12/2017	17/05/2018	12/07/2018	Dutch	PDF
Full modelCorrection	31/12/2016	17/05/2018	12/07/2018	Dutch	PDF
Full model	31/12/2016	02/05/2017	21/06/2017	Dutch	PDF
Full model	31/12/2015	03/05/2016	22/08/2016	Dutch	PDF
Full model	31/12/2014	05/05/2015	09/06/2015	Dutch	PDF
Full model	31/12/2013	05/05/2014	27/05/2014	Dutch	PDF
Full model	31/12/2012	06/05/2013	25/06/2013	Dutch	PDF
Full model	31/12/2011	15/05/2012	24/07/2012	Dutch	PDF
Full model	31/12/2010	06/05/2011	22/06/2011	Dutch	PDF
Full model	31/12/2009	06/05/2010	25/06/2010	Dutch	PDF
Full model	31/12/2008	06/05/2009	09/06/2009	Dutch	PDF
Full model	31/12/2007	15/05/2008	13/06/2008	Dutch	PDF
Full model	31/12/2006	08/05/2007	08/06/2007	Dutch	PDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 50 M€ and 100 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

6 active · 4 ended

Active mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
David J. Parker	Director20/02/2026 → 19/02/2032
Hidde Van Kerckhoven	Director20/01/2026 → 19/01/2032
Bart M.J. Peeters0871.617.848Represented by BART PEETERS	Managing director06/05/2021 → 06/05/2027Director04/01/2005 → 2017 accountsended
CREAFUND ASSET MANAGEMENT0679.859.835Represented by RUTH DE WULF	Director20/09/2018 → 06/05/2027
LEA SMETS	Director30/12/2003 → 06/05/2027
RAYMOND VAN GUCHT	Chairman of the board of directors06/05/2021 → 06/05/2027Managing director30/12/2003 → 2020 accountsended

Ended mandates

Director	Mandates in this company	Period	Other mandatescurrentendedstruck offbankruptcies
CREALOAN0470.551.057Represented by HERMAN WIELFAERT	Director20/09/2018 → 2018 accounts
True North Asset Management0457.827.330Represented by Bernard Hendrickx	Director25/06/2018 → 20/09/2018
IFC Services0843.336.905Represented by Johan Heirbrandt	Director06/05/2015 → 2015 accounts

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette

Mandates02/02/2026
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - DOEL - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
PDF
Mandates17/06/2025
ONTSLAGEN - BENOEMINGEN
PDF
Mandates23/04/2025
ONTSLAGEN - BENOEMINGEN
PDF
Other13/03/2024
STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, )
PDF
Mandates29/06/2022
ONTSLAGEN - BENOEMINGEN
PDF
Mandates30/08/2021
ONTSLAGEN - BENOEMINGEN
PDF
Mandates13/12/2019
ONTSLAGEN - BENOEMINGEN
PDF
Mandates22/05/2019
ONTSLAGEN - BENOEMINGEN
PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts

Year

Identity

Incorporation

Name

Registered office

Annual accounts

Filings18 filings

Mandates

David J. Parker

Hidde Van Kerckhoven

CREAFUND ASSET MANAGEMENT

Bart M.J. Peeters

RAYMOND VAN GUCHT

LEA SMETS

CREALOAN

True North Asset Management

IFC Services

NET CONSULTING

19861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032

Purna Pharmaceuticals

Rijksweg 17, 2870 Puurs-Sint-Amands

Director

Managing directorDirector

Chairman of the board of directorsManaging director

Director

CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE

Registered address	Period	Source
Rijksweg 17, 2870 Puurs-Sint-AmandsCurrent	accounts 2021 → 2025	Accounts 2025 · 2026-00140093

Company names

Source · NBB annual accounts, CBE

Name	Period	Source
Purna PharmaceuticalsCurrent	accounts 2021 → 2025	Accounts 2025 · 2026-00140093

Events

2025
Annual accounts 20252,8 M €↑
2024
Annual accounts 20242,7 M €↑
2023
Annual accounts 2023-3,4 M €↓
2022
Annual accounts 2022-745 k €↓
2021
Annual accounts 2021-575,6 k €↓
2020
Annual accounts 20201,9 M €↑
2019
Annual accounts 201932,5 k €↑
2018
Annual accounts 2018-1,5 M €↓
2017
Annual accounts 2017-378,2 k €↓
2016
Annual accounts 2016995,1 k €↑
2015
Annual accounts 2015284,7 k €↑
2014
Annual accounts 2014220 k €↓
2013
Annual accounts 2013310,7 k €↓
2012
Annual accounts 2012624,7 k €↑
2011
Annual accounts 2011270 k €↑
2010
Annual accounts 2010117,3 k €↑
2009
Annual accounts 2009-33,1 k €↓
2008
Annual accounts 2008353,5 k €
04/04/1986
IncorporationPublic limited company

Purna Pharmaceuticals

Overview

Identity

Financials

Valuation

Indicative valuation

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline

Timeline

Registered offices

Company names

Events